These results obtained in animal models have prompted a recent study on safety, tolerability, pharmacokinetics, pharmacodynamic, and efficacy of a monoclonal antibody against OPN in patients with RA [180]. The gene discussed is SPP1; the disease is rheumatoid arthritis.